Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

People With Heart Disease at Risk When Pharmacies Close
News | Antiplatelet and Anticoagulation Therapies | April 24, 2019
April 24, 2019 — New research from the University of Illinois at Chicago shows that when pharmacies close, people stop...
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
April 18, 2019 — A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second...
HonorHealth Research Institute Launches SynIVUS-DAPT Study
News | Antiplatelet and Anticoagulation Therapies | April 16, 2019
April 16, 2019 — HonorHealth Research Institute announced the first patients have been enrolled in the SynIVUS-DAPT...
Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance
News | Antiplatelet and Anticoagulation Therapies | April 15, 2019
April 15, 2019 — Despite national guidelines indicating statins can lower risk of heart attack and stroke, many...
Stopping DAPT After One Month Improved Outcomes in Stent Patients
News | Antiplatelet and Anticoagulation Therapies | March 25, 2019
March 25, 2019 — Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but...
Apixaban Effective in Specific Cohort of Non-Valvular Atrial Fibrillation Patients
News | Antiplatelet and Anticoagulation Therapies | March 19, 2019
March 19, 2019 — The Bristol-Myers Squibb-Pfizer Alliance announced results from the Phase 4 AUGUSTUS trial evaluating...
ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
March 18, 2019 — The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
February 19, 2019 — A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
January 2, 2019 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval...
Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018
December 17, 2018 — Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional...
Xarelto Reduces Blood Clot Events in High-Risk Cancer Patients
News | Cardio-oncology | December 07, 2018
December 7, 2018 — New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE...
Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
November 1, 2018 — A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes...
Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients
News | Stroke | October 31, 2018
October 31, 2018 — Recent statin and medication advances have led some researchers to suggest surgical treatments for...
Rivaroxaban (Xeralto) is now cleared by the FDA with a new indication is for patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).
Technology | Antiplatelet and Anticoagulation Therapies | October 17, 2018
October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban (...